Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.8
3.9
Journals
Biomedicines
Special Issues
New Advances in Oral Pathology and Medicine
share announcement

New Advances in Oral Pathology and Medicine

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 30 November 2026 | Viewed by 1885

Special Issue Editor

Dr. Christian Bacci

E-Mail Website
Guest Editor
Department of Neurosciences, University of Padova, Padova, Italy
Interests: oral pathology; oral medicine; oral surgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Recent advances in oral pathology have significantly improved our understanding and management of oral diseases. Modern imaging techniques provide clearer views of oral structures, enhancing diagnostic accuracy. Molecular methods now allow for precise identification of pathogens and genetic factors involved in oral conditions. The emergence of artificial intelligence in analyzing pathological data is streamlining diagnostic processes. New non-invasive diagnostic techniques are being developed, offering potential for earlier detection of oral cancers. Treatment options have expanded, with targeted therapies showing promise for various oral diseases. Additionally, regenerative medicine approaches are opening new avenues for oral tissue repair and reconstruction. These advancements are collectively transforming the field of oral pathology, leading to better patient outcomes.

Dr. Christian Bacci
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • molecular diagnostics
  • imaging technologies
  • artificial intelligence
  • targeted therapies
  • regenerative medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 4327 KB  
Article
Ionic Extracts of Magnesium Powders Promote In Vitro Lymphangiogenesis
by Yan Wang, Xiran Liu, Zerui Shan, Yu Xia, Yiya Weng, Magdalena M. Stevanović, Nenad Filipović, Kai Zheng and Junqing Ma
Biomedicines 2026, 14(4), 913; https://doi.org/10.3390/biomedicines14040913 - 16 Apr 2026
Viewed by 455
Abstract
Background/Objectives: Biodegradable magnesium (Mg)-based biomaterials release Mg2+ ions during degradation and may promote vascular-related regeneration. However, their effects on lymphatic endothelial cells (LECs) and lymphangiogenesis remain unclear. This study investigated whether magnesium powder-derived ionic extracts could enhance lymphangiogenesis-related behaviors of LECs in [...] Read more.
Background/Objectives: Biodegradable magnesium (Mg)-based biomaterials release Mg2+ ions during degradation and may promote vascular-related regeneration. However, their effects on lymphatic endothelial cells (LECs) and lymphangiogenesis remain unclear. This study investigated whether magnesium powder-derived ionic extracts could enhance lymphangiogenesis-related behaviors of LECs in vitro. Methods: Mg powder extracts were prepared and diluted for in vitro treatment. After viability screening, Mg (1:10), Mg (1:100), and Mg (1:1000) were selected for further analysis. LEC proliferation, migration, and tube formation were assessed, together with intracellular reactive oxygen species (ROS) levels and the expression of VEGFA, VEGFC, and VEGFR3. Results: Mg (1:10) and Mg (1:100) showed good cytocompatibility and significantly promoted LEC proliferation, migration, and tube formation compared with the control and Mg (1:1000) groups. These effects were accompanied by reduced intracellular ROS levels and increased expression of VEGFA, VEGFC, and VEGFR3. Conclusions: Magnesium powder-derived ionic extracts enhance lymphangiogenesis-related responses of LECs in vitro, particularly at the 1:10 and 1:100 dilutions. These findings support the potential of Mg-based biodegradable biomaterials for lymphatic tissue regeneration. Full article
(This article belongs to the Special Issue New Advances in Oral Pathology and Medicine)
►▼ Show Figures

Figure 1

12 pages, 923 KB  
Article
Possible Contribution of Oral Microbiota in the Osteonecrosis of the Jaw Induced by Zoledronate or Denosumab: A Preliminary Study
by Francesco Maria Erovigni, Alessandra Manca, Virginia Moscone, Miriam Antonucci, Valeria Ghisetti, Giorgia Menegatti, Francesco Chiara, Jacopo Mula, Alice Palermiti, Vittorio Fusco, Lorenzo Bianchi, Paolo Arduino, Antonio D’Avolio and Jessica Cusato
Biomedicines 2026, 14(4), 786; https://doi.org/10.3390/biomedicines14040786 - 30 Mar 2026
Viewed by 577
Abstract
Background/Objectives: Medication-related osteonecrosis of the jaw (MRONJ) is a clinically significant side effect related to antiresorptive therapies, such as denosumab and bisphosphonates. MRONJ may develop following oral surgical procedures or spontaneously. Although the pathophysiological processes underlying MRONJ are not well clarified, infections, [...] Read more.
Background/Objectives: Medication-related osteonecrosis of the jaw (MRONJ) is a clinically significant side effect related to antiresorptive therapies, such as denosumab and bisphosphonates. MRONJ may develop following oral surgical procedures or spontaneously. Although the pathophysiological processes underlying MRONJ are not well clarified, infections, commonly occurring after oral surgery, seem to have an important contribution in its development. Consequently, the role of the oral microbiota warrants investigation. This study investigates the possible contribution of the salivary microbiota to the onset of osteonecrosis in subjects treated with zoledronate or denosumab. Methods: Three groups of subjects were analyzed: patients treated with zoledronate or denosumab who had developed MRONJ (cases); those who did not (controls) and healthy subjects. Oral microbioma was evaluated through next-generation sequencing. Results: A total of 55 individuals were enrolled: 16 healthy subjects (29.1%), 21 controls (38.2%), and 18 cases (32.7%). Differences in the abundance of certain bacterial taxa were observed both among the three groups and in pairwise comparisons. Furthermore, a cut-off value of 5.51% for Streptococcus spp. was identified as being associated with the development of MRONJ. Conclusions: For the first time, this preliminary study highlights differences in the salivary microbiota among healthy subjects, controls, and cases, suggesting a potential cut-off value for Streptococcus spp. Despite the limited sample size, these findings provide initial insights. Further studies in larger cohorts are warranted. Full article
(This article belongs to the Special Issue New Advances in Oral Pathology and Medicine)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop